April 24, 2012 - Boston Scientific Corp. announces CE mark and European market launch of the Emerge PTCA Dilatation Catheter. The Emerge catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability to address challenging lesions. The company plans to launch the product immediately in CE mark countries in both monorail and over-the-wire (OTW) options. Commercial availability is expected in the United States and additional international markets later this year.

April 24, 2012—Providing more guidance to clinicians on the provision of optimal patient care, the American College of Cardiology Foundation (ACCF), American Heart Association (AHA) and American Medical Association–convened Physician Consortium for Performance Improvement (AMA-PCPI) released a publication highlighting updated performance measures for adults with heart failure (HF). The 2011 performance measures include care provided in both the outpatient and inpatient setting, emphasizing the need to measure care quality over time and across providers, while also focusing on patient outcomes.

April 24, 2012 – BioVentrix, the developer of minimally invasive therapies for the treatment of heart failure, will release this week the six-month results of a 26-patient trial demonstrating safety and feasibility of its proprietary system for use in EpiCardial Ventricular Restoration (ECVR). Results from the trial indicate that the BioVentrix system is an impactful method of treating heart failure caused by scarring of the left ventricle (LV) from a previous heartattack. This innovative approach reduces the size of the enlarged LV and restores its conical shape, thereby improving cardiac function without the need for a ventriculotomy or cardiopulmonary bypass (CPB).

April 24, 2012 - SeptRx, an emerging medical device company that has developed the SeptRx Intrapocket PFO Occluder (IPO) — a platform for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale (PFO) — reported that it has completed enrollment for its “InterSEPT” (In-tunnel SeptRx European PFO Trial) clinical trial in Europe, and has entered into a partnership with CoRRect Medical GmbH for commercial distribution in Germany and Switzerland of the SeptRx IPO.

April 23, 2012 - Abbott and St. Jude Medical announced ChoiceAlliance, a multi-year joint initiative that provides mutual U.S. customers
access to a robust portfolio of interventional cardiology, cardiac rhythm management, electrophysiology and intravascular imaging and diagnostic technologies.

April 23, 2012 - Boston Scientific Corp. announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release. This prospective, single-arm feasibility study enrolled 11 patients at three sites in Australia. Results from the REPRISE I trial are scheduled to be presented at the EuroPCR Congress in May.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now